Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients

NCT02650804 is registered in ClinicalTrials.gov with BPGbio as lead sponsor.

NCT NCT02650804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02650804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Lead sponsor
BPGbio
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2016
Completion date
June 11, 2019
Enrollment
45 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer